Capital with Purpose. Relationships that Matter.

Eliakim Capital is a private investment and strategic advisory firm that manages its own capital while working alongside select family offices and private investors to identify and support exceptional opportunities.

Experience Built Through Investing

Our investment experience spans life sciences, real estate, micro-cap companies, energy and artificial intelligence. We seek opportunities where experienced leadership, disciplined execution, and long-term fundamentals create the potential for lasting value.

Our track record reflects successful investments across these sectors, including an early investment in a medical device company that ultimately achieved a $160 million exit. As we continue to evolve our investment strategy, we are evaluating opportunities in artificial intelligence, data centers, and the space economy, while remaining disciplined in our commitment to long-term value creation.

We approach every opportunity from the perspective of an investor, not simply an advisor. That means emphasizing rigorous due diligence, disciplined decision-making, aligned interests, clear communication, and long-term stewardship of capital—principles that guide every investment decision and every relationship we build

Our Investment Focus

Eliakim Capital invests in opportunities where innovation, experienced leadership, and long-term market fundamentals create the potential for enduring value. While our investment experience spans multiple sectors, we remain disciplined and highly selective, evaluating each opportunity on its individual merits rather than following market trends. We believe successful investing begins with rigorous due diligence, strategic relationships, and a long-term perspective. Our objective is to identify exceptional companies and management teams positioned to solve meaningful problems while creating sustainable enterprise value.

Life Sciences

Life sciences represent one of Eliakim Capital's core areas of investment experience and long-term focus. The sector encompasses medical devices, biotechnology, biologics, diagnostics, and other healthcare innovations dedicated to improving patient outcomes and addressing some of the world's most significant medical challenges..

Medical Devices

Our investment experience includes identifying and supporting innovative medical device companies developing technologies that improve patient care while creating meaningful enterprise value. Our track record includes an early investment in Attune Medical, which was acquired by Haemonetics Corporation in a $160 million transaction.

Biotechnology

We believe biotechnology is entering one of the most significant periods of innovation in modern healthcare. Advances in peptide therapeutics, biologics, genomics, precision medicine, and AI-assisted drug discovery are accelerating the development of new therapies, while aging populations and the growing prevalence of chronic disease continue to drive long-term demand. We seek companies with differentiated science, experienced leadership, strong intellectual property, and a clear path toward clinical and commercial success.

Real Estate

Our real estate investment experience is built on 40 years of disciplined analysis, sound market fundamentals, and long-term value creation. We evaluate opportunities where quality assets, experienced operators, and strategic execution create durable investment potential.

Micro-Cap Companies
We selectively evaluate micro-cap companies where experienced management, differentiated business models, attractive valuations, and effective investor communications create opportunities for long-term value appreciation.

Artificial Intelligence
Artificial intelligence is reshaping how organizations operate, communicate, and compete, creating significant long-term investment opportunities across virtually every industry. Through our investment in Aria AI Labs, Eliakim Capital supports the practical application of AI while continuing to evaluate opportunities across the broader AI ecosystem, including agentic AI, digital infrastructure, and technologies that help organizations participate in the emerging machine economy.

Special Situations
Some of our most compelling opportunities fall outside traditional investment categories. We remain open to special situations where unique market dynamics, strategic relationships, or overlooked assets present the potential to create meaningful long-term value.

Evaluating New Opportunities
As we continue to evolve our investment strategy, we are evaluating opportunities in artificial intelligence, data centers, and the space economy. We believe these sectors represent significant long-term investment themes driven by technological innovation, expanding infrastructure needs, and global economic transformation.

ChatGPT Image Jul 12, 2026, 03_55_22 PM.png

Our Approach

Our investment philosophy is grounded in disciplined investing, long-term thinking, and trusted relationships. Every opportunity is evaluated through the perspective of an investor, emphasizing rigorous due diligence, strategic alignment, and sustainable value creation.

Investing Alongside Our Partners

Every opportunity is evaluated with the same discipline, accountability, and long-term perspective we apply when investing our own capital. We believe the strongest investment decisions are made when interests are aligned and relationships are built on trust.

Disciplined Selectivity

We believe meaningful partnerships begin with selectivity. Rather than pursuing volume, we intentionally focus on a limited number of opportunities where our experience, strategic relationships, and long-term perspective can create meaningful value.

Alignment of Interests

Successful investments begin with shared objectives, transparency, clear communication, and mutual trust. Strong alignment among investors, founders, management teams, and stakeholders creates the foundation for enduring partnerships and better long-term outcomes.

Long-Term Stewardship

Building lasting value requires patience, discipline, and thoughtful execution. Every investment is approached with a long-term perspective, recognizing that meaningful results are achieved through sound decision-making and responsible stewardship rather than short-term activity.

Relationships Built Over Decades

Our network has been cultivated over decades through investing, life sciences, real estate, technology, government, national security, governance, and nonprofit leadership. These trusted relationships continue to provide valuable insights, strategic connections, and opportunities that help exceptional companies achieve long-term success.

Preparing for the Agentic Economy

“AI is no longer a single breakthrough or application—it is essential infrastructure. Every company will use it. Every nation will build it.”

— Jensen Huang, Founder and CEO, NVIDIA

As Eliakim Capital evaluates investment opportunities across the artificial intelligence ecosystem, we also support affiliated companies helping organizations apply AI in practical, measurable ways.

ARIA AI Labs

ChatGPT Image Jul 12, 2026, 04_52_09 PM.png

ARIA AI Labs helps companies strengthen investor communications, thought leadership, and market visibility by transforming existing business materials into clear, consistent, investor-ready content. Its autonomous media capabilities also enable organizations to build and operate full digital publications using agentic AI.

Explore ARIA AI Labs

Agentic Commerce Readiness Assessment

ChatGPT Image Jun 28, 2026, 01_58_18 AM (2).png

The Agentic Commerce Readiness Assessment (ACRA), offered by Adam Silva Consulting, helps organizations determine whether their digital infrastructure is prepared for a world in which AI agents increasingly discover, evaluate, and transact with businesses. The assessment identifies readiness gaps and provides a practical roadmap for participating in the emerging agentic economy.

Get an ACRA Report

Insights

Why Google's AI Brain Drain Could Reshape the Entire AI Infrastructure Market

Nobel Prize winning researchers do not quietly update their professional profiles on a Friday unless something has shifted in a way that cannot be walked back. John Jumper, who shared the 2024 Nobel Prize in Chemistry for AlphaFold, arguably the most consequential AI driven scientific breakthrough of the decade, recently announced he is leaving Google DeepMind after nearly nine years to join Anthropic. He is not the only one. Jonas Adler and Alexander Pritzel followed within

The Hidden Costs of VMware: Why Enterprises Are Paying Billions More

Earlier this year, T-Mobile sued Broadcom over VMware support for tens of thousands of virtual machines running across more than 300,000 CPU cores. The number is striking, but the more important detail is that T-Mobile is not an isolated case. It is the third major enterprise in two years to end up in litigation over the same issue: what happens when a company builds its entire operational stack on top of a single vendor, and that vendor changes the terms. For investors focus

From Discovery to Philanthropy: How Indianapolis Helped Shape the Modern Biologics Revolution

Scientific breakthroughs often change medicine. Occasionally, they also reshape economies, create entirely new industries, and generate wealth that benefits society for generations. Few places illustrate that better than Indianapolis. For more than a century, the city has quietly stood at the forefront of biologics innovation, producing discoveries that have transformed the treatment of diabetes, depression, obesity, and countless other diseases. Along the way, those scientif

100 Agents for Every Employee: Jensen Huang's Vision for the Post-Human-Scale Workforce

At NVIDIA's GTC conference earlier this year, Jensen Huang told a room full of media something that should reframe how every executive thinks about headcount planning. In ten years, he said, NVIDIA expects to have around 75,000 employees, roughly double its current workforce. Those employees will be working alongside 7.5 million AI agents. A 100-to-1 ratio. Not 100 agents replacing employees. Ratio to employees. That single number is the clearest signal yet of where Huang bel

Microcap 101: The Case for the Market's Most Overlooked Segment

Most investors know what a microcap stock is in the abstract. Far fewer understand why serious, experienced investors dedicate careers to this corner of the market. This piece covers both: the fundamentals of what microcap stocks are and where they trade, and the core investment thesis that draws disciplined capital to the space. This content is for informational and educational purposes only and does not constitute financial advice. Please consult a licensed financial profes

The Biologics Revolution: How Peptides, Semaglutides, and a Radical New Science Are Rewriting Pharmaceutical History

For most of pharmaceutical history, the dominant paradigm was simple: identify a disease process, synthesize a small chemical molecule to block or mimic it, and deliver the drug orally. The pill was the product. The chemistry was the science. And for decades, this model produced real results controlling blood pressure, suppressing inflammation, managing chronic pain. But control is not cure. And an industry built on managing symptoms rather than correcting the underlying biol

Contact